Illumina (ILMN) said Monday it started a pilot proteomics program to analyze 50,000 UK Biobank samples in partnership with deCODE Genetics, Standard BioTools, Tecan, GSK (GSK), Johnson & Johnson (JNJ), and Novartis (NVS).
Under the collaboration, deCODE Genetics will process the samples from the UK Biobank using Illumina's Protein Prep solution, the company said.
The data generated from the study will be made available to the scientific research community, with the first tranche of the data expected to be released in H2.
Illumina Protein Prep has been in early access limited release and is expected to fully launch in H1.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。